Get Real Time Here
| Open- | Close- |
| Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
| Day Range- - - | 52 Wk Range14.965 - 39.850 |
Kymera Therapeutics Stock (NASDAQ:KYMR), Quotes and News Summary
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
| Open- | Close- |
| Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
| Day Range- - - | 52 Wk Range14.965 - 39.850 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.710 | -0.670 | 0.0400 | ||||
| REV | 14.060M | 16.513M | 2.453M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
| 2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
| 2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
| 2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| KYMR | Kymera Therapeutics | 0% | 845M |
| VALN | Valneva | 0% | 880.6M |
| COGT | Cogent Biosciences | 0% | 852.1M |
| AMAM | Ambrx Biopharma | 0% | 666M |
| REPL | Replimune Group | 0% | 952.8M |
How do I buy Kymera Therapeutics (KYMR) stock?
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Who are Kymera Therapeutics's (KYMR) competitors?
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Kymera Therapeutics (KYMR) stock?
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
Current Stock Price for Kymera Therapeutics (KYMR)?
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
Does Kymera Therapeutics (KYMR) pay a dividend?
There is no dividend information for Kymera Therapeutics.
When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
Is Kymera Therapeutics (KYMR) going to split?
There is no upcoming split for Kymera Therapeutics.
What sector and industry does Kymera Therapeutics (KYMR) operate in?
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ:KYMR), Quotes and News Summary
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
| Open- | Close- |
| Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
| Day Range- - - | 52 Wk Range14.965 - 39.850 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.710 | -0.670 | 0.0400 | ||||
| REV | 14.060M | 16.513M | 2.453M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
| 2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
| 2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
| 2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| KYMR | Kymera Therapeutics | 0% | 845M |
| VALN | Valneva | 0% | 880.6M |
| COGT | Cogent Biosciences | 0% | 852.1M |
| AMAM | Ambrx Biopharma | 0% | 666M |
| REPL | Replimune Group | 0% | 952.8M |
How do I buy Kymera Therapeutics (KYMR) stock?
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Who are Kymera Therapeutics's (KYMR) competitors?
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Kymera Therapeutics (KYMR) stock?
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
Current Stock Price for Kymera Therapeutics (KYMR)?
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
Does Kymera Therapeutics (KYMR) pay a dividend?
There is no dividend information for Kymera Therapeutics.
When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
Is Kymera Therapeutics (KYMR) going to split?
There is no upcoming split for Kymera Therapeutics.
What sector and industry does Kymera Therapeutics (KYMR) operate in?
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ:KYMR), Quotes and News Summary
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
| Open- | Close- |
| Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
| Day Range- - - | 52 Wk Range14.965 - 39.850 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.710 | -0.670 | 0.0400 | ||||
| REV | 14.060M | 16.513M | 2.453M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
| 2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
| 2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
| 2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| KYMR | Kymera Therapeutics | 0% | 845M |
| VALN | Valneva | 0% | 880.6M |
| COGT | Cogent Biosciences | 0% | 852.1M |
| AMAM | Ambrx Biopharma | 0% | 666M |
| REPL | Replimune Group | 0% | 952.8M |
How do I buy Kymera Therapeutics (KYMR) stock?
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Who are Kymera Therapeutics's (KYMR) competitors?
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Kymera Therapeutics (KYMR) stock?
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
Current Stock Price for Kymera Therapeutics (KYMR)?
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
Does Kymera Therapeutics (KYMR) pay a dividend?
There is no dividend information for Kymera Therapeutics.
When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
Is Kymera Therapeutics (KYMR) going to split?
There is no upcoming split for Kymera Therapeutics.
What sector and industry does Kymera Therapeutics (KYMR) operate in?
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ:KYMR), Quotes and News Summary
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
| Open- | Close- |
| Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
| Day Range- - - | 52 Wk Range14.965 - 39.850 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.710 | -0.670 | 0.0400 | ||||
| REV | 14.060M | 16.513M | 2.453M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
| 2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
| 2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
| 2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| KYMR | Kymera Therapeutics | 0% | 845M |
| VALN | Valneva | 0% | 880.6M |
| COGT | Cogent Biosciences | 0% | 852.1M |
| AMAM | Ambrx Biopharma | 0% | 666M |
| REPL | Replimune Group | 0% | 952.8M |
How do I buy Kymera Therapeutics (KYMR) stock?
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Who are Kymera Therapeutics's (KYMR) competitors?
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Kymera Therapeutics (KYMR) stock?
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
Current Stock Price for Kymera Therapeutics (KYMR)?
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
Does Kymera Therapeutics (KYMR) pay a dividend?
There is no dividend information for Kymera Therapeutics.
When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
Is Kymera Therapeutics (KYMR) going to split?
There is no upcoming split for Kymera Therapeutics.
What sector and industry does Kymera Therapeutics (KYMR) operate in?
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ:KYMR), Quotes and News Summary
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
| Open- | Close- |
| Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
| Day Range- - - | 52 Wk Range14.965 - 39.850 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.710 | -0.670 | 0.0400 | ||||
| REV | 14.060M | 16.513M | 2.453M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
| 2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
| 2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
| 2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| KYMR | Kymera Therapeutics | 0% | 845M |
| VALN | Valneva | 0% | 880.6M |
| COGT | Cogent Biosciences | 0% | 852.1M |
| AMAM | Ambrx Biopharma | 0% | 666M |
| REPL | Replimune Group | 0% | 952.8M |
How do I buy Kymera Therapeutics (KYMR) stock?
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Who are Kymera Therapeutics's (KYMR) competitors?
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Kymera Therapeutics (KYMR) stock?
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
Current Stock Price for Kymera Therapeutics (KYMR)?
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
Does Kymera Therapeutics (KYMR) pay a dividend?
There is no dividend information for Kymera Therapeutics.
When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
Is Kymera Therapeutics (KYMR) going to split?
There is no upcoming split for Kymera Therapeutics.
What sector and industry does Kymera Therapeutics (KYMR) operate in?
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ:KYMR), Quotes and News Summary
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
| Open- | Close- |
| Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
| Day Range- - - | 52 Wk Range14.965 - 39.850 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.710 | -0.670 | 0.0400 | ||||
| REV | 14.060M | 16.513M | 2.453M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
| 2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
| 2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
| 2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| KYMR | Kymera Therapeutics | 0% | 845M |
| VALN | Valneva | 0% | 880.6M |
| COGT | Cogent Biosciences | 0% | 852.1M |
| AMAM | Ambrx Biopharma | 0% | 666M |
| REPL | Replimune Group | 0% | 952.8M |
How do I buy Kymera Therapeutics (KYMR) stock?
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Who are Kymera Therapeutics's (KYMR) competitors?
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Kymera Therapeutics (KYMR) stock?
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
Current Stock Price for Kymera Therapeutics (KYMR)?
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
Does Kymera Therapeutics (KYMR) pay a dividend?
There is no dividend information for Kymera Therapeutics.
When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
Is Kymera Therapeutics (KYMR) going to split?
There is no upcoming split for Kymera Therapeutics.
What sector and industry does Kymera Therapeutics (KYMR) operate in?
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ:KYMR), Quotes and News Summary
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
| Open- | Close- |
| Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
| Day Range- - - | 52 Wk Range14.965 - 39.850 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.710 | -0.670 | 0.0400 | ||||
| REV | 14.060M | 16.513M | 2.453M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
| 2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
| 2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
| 2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| KYMR | Kymera Therapeutics | 0% | 845M |
| VALN | Valneva | 0% | 880.6M |
| COGT | Cogent Biosciences | 0% | 852.1M |
| AMAM | Ambrx Biopharma | 0% | 666M |
| REPL | Replimune Group | 0% | 952.8M |
How do I buy Kymera Therapeutics (KYMR) stock?
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Who are Kymera Therapeutics's (KYMR) competitors?
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Kymera Therapeutics (KYMR) stock?
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
Current Stock Price for Kymera Therapeutics (KYMR)?
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
Does Kymera Therapeutics (KYMR) pay a dividend?
There is no dividend information for Kymera Therapeutics.
When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
Is Kymera Therapeutics (KYMR) going to split?
There is no upcoming split for Kymera Therapeutics.
What sector and industry does Kymera Therapeutics (KYMR) operate in?
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ:KYMR), Quotes and News Summary
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
| Open- | Close- |
| Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
| Day Range- - - | 52 Wk Range14.965 - 39.850 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.710 | -0.670 | 0.0400 | ||||
| REV | 14.060M | 16.513M | 2.453M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
| 2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
| 2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
| 2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| KYMR | Kymera Therapeutics | 0% | 845M |
| VALN | Valneva | 0% | 880.6M |
| COGT | Cogent Biosciences | 0% | 852.1M |
| AMAM | Ambrx Biopharma | 0% | 666M |
| REPL | Replimune Group | 0% | 952.8M |
How do I buy Kymera Therapeutics (KYMR) stock?
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Who are Kymera Therapeutics's (KYMR) competitors?
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Kymera Therapeutics (KYMR) stock?
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
Current Stock Price for Kymera Therapeutics (KYMR)?
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
Does Kymera Therapeutics (KYMR) pay a dividend?
There is no dividend information for Kymera Therapeutics.
When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
Is Kymera Therapeutics (KYMR) going to split?
There is no upcoming split for Kymera Therapeutics.
What sector and industry does Kymera Therapeutics (KYMR) operate in?
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kymera Therapeutics Stock (NASDAQ:KYMR), Quotes and News Summary
Kymera Therapeutics Stock (NASDAQ: KYMR) stock price, news, charts, stock research, profile.
| Open- | Close- |
| Vol / Avg.0 / 397.053K | Mkt Cap845.038M |
| Day Range- - - | 52 Wk Range14.965 - 39.850 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.710 | -0.670 | 0.0400 | ||||
| REV | 14.060M | 16.513M | 2.453M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-29 | Morgan Stanley | James Quigley | Maintains | Equal-WeightEqual-Weight | Lowers | 39.00 | 37.00 |
| 2023-08-07 | Stifel | Bradley Canino | Maintains | BuyBuy | Raises | 48.00 | 52.00 |
| 2023-08-04 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 36.00 | 37.00 |
| 2023-08-04 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 85.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| KYMR | Kymera Therapeutics | 0% | 845M |
| VALN | Valneva | 0% | 880.6M |
| COGT | Cogent Biosciences | 0% | 852.1M |
| AMAM | Ambrx Biopharma | 0% | 666M |
| REPL | Replimune Group | 0% | 952.8M |
How do I buy Kymera Therapeutics (KYMR) stock?
You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.
Who are Kymera Therapeutics's (KYMR) competitors?
Other companies in Kymera Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Replimune Group (NASDAQ:REPL) and Immatics (NASDAQ:IMTX).
What is the target price for Kymera Therapeutics (KYMR) stock?
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Morgan Stanley on Tuesday, August 29, 2023. The analyst firm set a price target for 37.00 expecting KYMR to rise to within 12 months (a possible 142.62% upside). 21 analyst firms have reported ratings in the last year.
Current Stock Price for Kymera Therapeutics (KYMR)?
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $15.25 last updated September 25, 2023 at 8:00 PM UTC.
Does Kymera Therapeutics (KYMR) pay a dividend?
There is no dividend information for Kymera Therapeutics.
When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?
Kymera Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
Is Kymera Therapeutics (KYMR) going to split?
There is no upcoming split for Kymera Therapeutics.
What sector and industry does Kymera Therapeutics (KYMR) operate in?
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.